Neticonazole hydrochloride

CAS: 130773-02-3 F: C17H23ClN2OS W: 338.90

Neticonazole hydrochloride is an imidazole derivative and a potent and long-acting antifungal agent. Neticonazole hydroc

Contact QiTai

This product is for research use only, not for human use. We do not sell to patients.

Bioactivity	Neticonazole hydrochloride is an imidazole derivative and a potent and long-acting antifungal agent. Neticonazole hydrochloride has anti-infection and anti-cancer effects[1][2][3].
Target	Fungal
Invitro	Neticonazole (10 µM; 48 hours; C4-2B cells) treatment decreases the levels of both Alix and Rab27a, and significantly decreases nSMase2 levels. Neticonazole causes a significant inhibition in p-ERK levels[2].Neticonazole (0-10 µM) exhibits a potent and dose-dependent inhibition of exosome release from C4-2B cells[2].Neticonazole hydrochloride is also an orally active exosome biogenesis and secretion inhibitor[3]. Western Blot Analysis[2] Cell Line:
In Vivo	Neticonazole (1-100 ng/kg; oral gavage; daily; for 15 days; male C57BL/6 mice) treatment significantly improves the survival of intestinal dysbacteriosis (IDB) mice with colorectal cancer (CRC) xenograft tumors, likely through increasing apoptosis of CRC xenograft tumor cells[3]. Animal Model:
Name	Neticonazole hydrochloride
CAS	130773-02-3
Formula	C17H23ClN2OS
Molar Mass	338.90
Appearance	Solid
Transport	Room temperature in continental US; may vary elsewhere.
Storage	4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Reference	[1]. Tsuboi R, et al. Hyperkeratotic chronic tinea pedis treated with neticonazole cream. Neticonazole Study Group. Int J Dermatol. 1996 May;35(5):371-3. [2]. Datta A, et al. High-throughput screening identified selective inhibitors of exosome biogenesis and secretion: A drug repurposing strategy for advanced cancer. Sci Rep. 2018 May 25;8(1):8161. [3]. Gu L, et al. The exosome secretion inhibitor neticonazole suppresses intestinal dysbacteriosis-induced tumorigenesis of colorectal cancer. Invest New Drugs. 2020 Apr;38(2):221-228.